US 12,403,118 B1
Cancer treatments using modified fatty acids and the carriers to administer them
Bryan S. Margulies, Liverpool, NY (US); and Joe C. Loy, Weatherford, TX (US)
Assigned to Zetagen Therapeutics, Inc., Syracuse, NY (US)
Filed by Zetagen Therapeutics, Inc., Syracuse, NY (US)
Filed on Mar. 5, 2025, as Appl. No. 19/071,647.
Int. Cl. A61K 31/28 (2006.01); A61K 31/485 (2006.01); A61K 45/06 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/36 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/28 (2013.01) [A61K 31/485 (2013.01); A61K 45/06 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/36 (2013.01); A61P 35/00 (2018.01)] 5 Claims
 
1. A lanthanide (III) 9-R′, 10-R″ tri octadecanoate compound of the formula:

OG Complex Work Unit Chemistry